Press Releases
Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at 2010 ARVO Annual Meeting
BEDFORD, MA — April 29, 2010 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that new preclinical data on its resolvin drug candidates will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2010 Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.
Resolvins have a unique mechanism with the potential to treat both ocular surface and retinal diseases. Resolvyx will make presentations at three sessions at this year’s ARVO annual meeting, continuing the interest in resolvin data from the five presentations at last year’s 2009 ARVO meeting.
The schedule and meeting place for the sessions, together with the abstract information, are listed below:
Date & Time: Monday, May 3, 2010, 1:45 – 3:30 PM
Session Title: Corneal Epithelium
Session Number: 267
Abstract: 1950/D881
Title: Resolvin Ameliorates Hypertonicity-Induced Inflammation and Protects Against Losses in Human Corneal Epithelial Cell Barrier Function
Location: Exhibit Hall B/C
Date & Time: Wednesday, May 5, 2010, 8:30 - 10:15 AM
Session Title: Corneal Infections: Experimental I
Session Number: 411
Abstract: 3867/A3
Title: Application of Resolvin E1 Modulates the Severity of HSV-Induced Corneal Immunopathology
Location: Exhibit Hall B/C
Date & Time: Thursday, May 6, 2010, 11:15 - 1:00 PM
Session Title: AMD – Basic Mechanisms
Session Number: 554
Abstract: 6185/D697
Title: Cell Specific Targeting by NPD1 Induces Resolution of CNV Injury
Location: Exhibit Hall B/C
About Resolvins
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed. Resolvins are shown to be highly potent and efficacious in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.
Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (e.g. Crohn's disease, psoriasis and rheumatoid arthritis), allergic diseases (e.g. asthma) and chronic inflammatory diseases (e.g. atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer's disease). Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression. Resolvyx currently has two programs in clinical development. RX-10045 is a topical eye drop that has completed a Phase 2 trial in chronic dry eye. RX-10001 is formulated for oral delivery and has completed Phase 1.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of over 80 patents and applications.
The company's headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com.